Chang P, Gálvez D

Language: Spanish
References: 26
Page: 172-177
PDF size: 329.62 Kb.

ABSTRACT

Introduction: The proximal nail fold is a structure of the nail apparatus that can also be affected by drug reactions.
Objective: To present the clinical experience in drug reactions with involvement of the proximal nail fold.
Materials and methods: We carried out a transversal and prospective-retrospective study with 13 patients with a drug reactions studied at the Hospital General de Enfermedades (IGSS) and Hospital Los Angeles in Guatemala City. Besides the cutaneous or mucosae involvement, the proximal nail fold was also affected. All of them were studied from 2006 till 2009. We performed a careful dermatological examination on fingernails and toenails without reporting any other nail abnormality.
Results: Thirteen patients were studied, nine males (69.2%) and four females (30.7%). Proximal toe nail fold involvement in six (46.1%), fingernail in four (30.7%), with finger and toe nails in three (23.0%). The drug reactions with affection of the proximal nail fold were Stevens Johnson syndrome five patients (38.4%), fixed drug eruption in four (30.7%), melanodermia due to cytostatic drugs, in two (15.3%), periungual erythema, and photosensitivity one case each (7.69%).
Conclusions: The proximal nail fold can be affected in drug reactions as previously reported.

REFERENCES

1. Alonzo L, López L. “Diagnóstico diferencial de reacciones medicamentosas adversas”. Rev Cent Dermatol Pascua. 2000; 9(2): 120-124.

2. Aldama A, Gorostiaga G, Rivelli V, Mendoza G. “Formas graves y mortales de las farmacodermias. A propósito de 53 casos”. www. redaccionmedica.com/formacion/farmacodermias_2.pdf, consultado el 7 de noviembre de 2009.

3. Mayorga C, Torres M, Fernández J, Sánchez Sabate E, Álvarez J, Mayorga C, Fernández J. “Cutaneous symptoms in drug allergy: What PATRICIA CHANG y col REAC C IONES M EDICAMENTOSAS have we learnt?”. Current Opinion in Allergy and Clinical Immunology. 2009; 9: 431-436.

4. Gruchalla R. “Undestanding drug allergies”. J Allergy Clin Immunol. 2000; 105(6) S1: 637-644.

5. Martín R, Marcano M, Sardi J, Ball, Giansante E. “Síndrome de hipersensibilidad inducido por fármacos. Revisión de 3 años en el Servicio de Dematología del Hospital Universitario de Caracas, Venezuela”. Dermatología Venezolana. 2008; 46(1): 18-23.

6. Gerson D, Sriganeshan V, Alexis J. “Cutaneous drug eruptions: A 5-year experience”. J Am Acad Dermatol. 2008; 59(6): 995-999.

7. Shear N, Knowles S, Sullivan J, Shapiro L. “Cutaneous reactions to drugs”. En: K Wolff, L Goldsmith, S Katz et al. Fitzpatrick’s Dermatology in General Medicine, Nueva York, McGraw-Hill, 2008: 355-361.

8. Rozieres A, Vocanson M, Ben B et al. “Role of T cells in non immediate allergic drug reactions”. Current Opinion in Allergy and Clinical Immunology. 2009; 9: 305-310.

9. García Patos Briones V, García D. “Toxicodermias” www.aeped.es/ protocolos/dermatologia/tres/toxicodermias.pdf consultado el 27 de noviembre de 2009.

10. Roujeau J. “Clinical heterogeneity of drug hypersensitivity”. Toxicology. 2005; 209: 123-129.

11. Dawber RPR. Berker D, Baran R. “Science of the nail apparatus”. En: R Baran, RPR Dawber, D de Berker et al. Diseases of fhe Nails and their Management, Londres, Blackwell Science Publications, 2001: 11-21.

12. Tosti A, Baran R, Dawber R. “The nail in systemic diseases and druginduced changes”. En: R Baran, RPR Dawber, D de Berker et al. Diseases of the Nails and their Management, Londres. Blackwell Science Publications, 2001: 302-329.

13. Chang P, Borjas C. “Onicopatía por capecitabina”. Dermatología Cosmética, Médica y Quirúrgica. 2009; 7(2): 141-144.

14. Alonzo L, López L. “Diagnóstico diferencial de reacciones medicamentosas adversas”. Rev Cent Dermatol Pascua. 2000; 9(2): 120-124.

15. Aldama A, Gorostiaga G, Rivelli V, Mendoza G. “Formas graves y mortales de las farmacodermias. A propósito de 53 casos”. www. redaccionmedica.com/formacion/farmacodermias_2.pdf, consultado el 7 de noviembre de 2009.

16. Mayorga C, Torres M, Fernández J, Sánchez Sabate E, Álvarez J, Mayorga C, Fernández J. “Cutaneous symptoms in drug allergy: What PATRICIA CHANG y col REAC C IONES M EDICAMENTOSAS have we learnt?”. Current Opinion in Allergy and Clinical Immunology. 2009; 9: 431-436.

17. Gruchalla R. “Undestanding drug allergies”. J Allergy Clin Immunol. 2000; 105(6) S1: 637-644.

18. Martín R, Marcano M, Sardi J, Ball, Giansante E. “Síndrome de hipersensibilidad inducido por fármacos. Revisión de 3 años en el Servicio de Dematología del Hospital Universitario de Caracas, Venezuela”. Dermatología Venezolana. 2008; 46(1): 18-23.

19. Gerson D, Sriganeshan V, Alexis J. “Cutaneous drug eruptions: A 5-year experience”. J Am Acad Dermatol. 2008; 59(6): 995-999.

20. Shear N, Knowles S, Sullivan J, Shapiro L. “Cutaneous reactions to drugs”. En: K Wolff, L Goldsmith, S Katz et al. Fitzpatrick’s Dermatology in General Medicine, Nueva York, McGraw-Hill, 2008: 355-361.

21. Rozieres A, Vocanson M, Ben B et al. “Role of T cells in non immediate allergic drug reactions”. Current Opinion in Allergy and Clinical Immunology. 2009; 9: 305-310.

22. García Patos Briones V, García D. “Toxicodermias” www.aeped.es/ protocolos/dermatologia/tres/toxicodermias.pdf consultado el 27 de noviembre de 2009.

23. Roujeau J. “Clinical heterogeneity of drug hypersensitivity”. Toxicology. 2005; 209: 123-129.

24. Dawber RPR. Berker D, Baran R. “Science of the nail apparatus”. En: R Baran, RPR Dawber, D de Berker et al. Diseases of fhe Nails and their Management, Londres, Blackwell Science Publications, 2001: 11-21.

25. Tosti A, Baran R, Dawber R. “The nail in systemic diseases and druginduced changes”. En: R Baran, RPR Dawber, D de Berker et al. Diseases of the Nails and their Management, Londres. Blackwell Science Publications, 2001: 302-329.

26. Chang P, Borjas C. “Onicopatía por capecitabina”. Dermatología Cosmética, Médica y Quirúrgica. 2009; 7(2): 141-144.